ATE190657T1 - Immunogenes hybridprotein oprf-oprl erhältlich aus membranproteinen von pseudomonas aeruginosa - Google Patents

Immunogenes hybridprotein oprf-oprl erhältlich aus membranproteinen von pseudomonas aeruginosa

Info

Publication number
ATE190657T1
ATE190657T1 AT95118098T AT95118098T ATE190657T1 AT E190657 T1 ATE190657 T1 AT E190657T1 AT 95118098 T AT95118098 T AT 95118098T AT 95118098 T AT95118098 T AT 95118098T AT E190657 T1 ATE190657 T1 AT E190657T1
Authority
AT
Austria
Prior art keywords
pseudomonas aeruginosa
hybrid protein
oprl
available
membrane proteins
Prior art date
Application number
AT95118098T
Other languages
English (en)
Inventor
Bernhard Dr Knapp
Klaus-Dieter Dr Hungerer
Michael Dr Broeker
Specht Bernd Ulrich Prof Von
Horst Prof Domdey
Original Assignee
Chiron Behring Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Behring Gmbh & Co filed Critical Chiron Behring Gmbh & Co
Application granted granted Critical
Publication of ATE190657T1 publication Critical patent/ATE190657T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/823—Bacterial vaccine for bovine species, e.g. cattle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/824—Bacterial vaccine for ovine species, e.g. sheep
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/826—Bacterial vaccine for avian species, e.g. poultry or other birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/829—Bacterial vaccine for equine species, e.g. horses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT95118098T 1994-12-16 1995-11-17 Immunogenes hybridprotein oprf-oprl erhältlich aus membranproteinen von pseudomonas aeruginosa ATE190657T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94120023 1994-12-16

Publications (1)

Publication Number Publication Date
ATE190657T1 true ATE190657T1 (de) 2000-04-15

Family

ID=8216542

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95118098T ATE190657T1 (de) 1994-12-16 1995-11-17 Immunogenes hybridprotein oprf-oprl erhältlich aus membranproteinen von pseudomonas aeruginosa

Country Status (8)

Country Link
US (2) US5955090A (de)
EP (1) EP0717106B1 (de)
JP (2) JP3712244B2 (de)
KR (1) KR960022559A (de)
AT (1) ATE190657T1 (de)
AU (1) AU4041995A (de)
CA (1) CA2165401C (de)
DE (1) DE69515613T2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU707657B2 (en) * 1995-02-09 1999-07-15 Behringwerke Aktiengesellschaft Process for the production of proteins
GB9701489D0 (en) 1997-01-24 1997-03-12 Auspharm Int Ltd Antigen
KR100461710B1 (ko) * 1997-09-13 2005-09-28 씨제이 주식회사 신규한 녹농균 세포 외막 단백질 유전자 및 이를 이용한 녹농균 감염 예방용 백신 및 녹농균 감염증 치료제
GB9915044D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
EP1078988A1 (de) * 1999-08-27 2001-02-28 Academia Sinica Pseudomonas Fusionsprotein-Impstoff
AU2001248314B2 (en) * 2000-02-18 2004-08-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens
AU2002211201B2 (en) * 2000-11-02 2007-05-31 The National University Of Singapore aopB Gene, protein, homologs, fragments and variants thereof, and their use for cell surface display
JP2002316944A (ja) * 2001-04-17 2002-10-31 Chemo Sero Therapeut Res Inst ヒトポリクローナル抗体組成物
EP1790659B1 (de) 2001-11-13 2013-07-31 ID Biomedical Corporation Pseudomonas aeruginosa Polypeptide
ES2431318T3 (es) * 2001-11-13 2013-11-26 Id Biomedical Corporation Polipéptidos de Pseudomonas aeruginosa
US7405039B2 (en) 2002-02-07 2008-07-29 Austin Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
WO2003087351A1 (en) 2002-04-12 2003-10-23 Melbourne Health Hepatitis b viral variants with redused susceptibility to nucleoside analogs and uses thereof
JP2008534020A (ja) 2005-04-08 2008-08-28 メルボルン ヘルス 抗ウイルス性のヌクレオシド剤に耐性を示すｂ型肝炎ウイルスのバリアントおよびその応用法
AU2006230802A1 (en) 2005-04-08 2006-10-12 Austin Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
JPWO2007049770A1 (ja) 2005-10-28 2009-04-30 明治製菓株式会社 緑膿菌の外膜タンパク質ｐａ５１５８
US20080090760A2 (en) * 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
JPWO2007114340A1 (ja) 2006-03-30 2009-08-20 明治製菓株式会社 緑膿菌の外膜タンパク質ｐａ０４２７
SG182975A1 (en) * 2007-06-29 2012-08-30 Meiji Seika Kaisha Pseudomonas aeruginosa outer membrane protein pa4710
EP2236515A4 (de) 2007-12-25 2012-10-31 Meiji Seika Kaisha Komponentenprotein pa1698 für das typ-iii-sekretionssystem von pseudomonas aeruginosa
EP2408475B1 (de) 2009-03-18 2017-11-15 Wake Forest University Health Sciences Flagellin-fusionsproteine und ihre verwendung zur auslösung von immunantworten gegen pseudomonas aeruginosa
CN103270047A (zh) * 2010-12-23 2013-08-28 因特塞尔奥地利股份公司 Oprf/i剂及其在住院患者和其他患者中的用途
EP2686339A1 (de) * 2011-03-18 2014-01-22 Valneva Austria GmbH Neue oprf/i-fusionsproteine, ihre herstellung und verwendung
RU2529359C2 (ru) * 2012-09-19 2014-09-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" Российской академии медицинских наук (ФГБУ "НИИВС им. И.И. Мечникова" РАМН) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pPA-OPRF-ETA, КОДИРУЮЩАЯ СИНТЕЗ РЕКОМБИНАНТНОГО БЕЛКА OPRF-ETA Pseudomonas aeruginosa, ШТАММ Escherichia coli PA-OPRF-ETA - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО БЕЛКА OPRF-ETA Pseudomonas aeruginosa И СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО БЕЛКА OPRF-ETA Pseudomonas aeruginosa
SMT201800011T1 (it) * 2012-11-30 2018-05-02 Glaxosmithkline Biologicals Sa Antigeni e combinazioni di antigeni di pseudomonas
CN107073096A (zh) * 2014-08-29 2017-08-18 索伦托治疗有限公司 结合OprF和OprI的抗体治疗
WO2016193402A1 (en) * 2015-06-03 2016-12-08 Valneva Austria Gmbh Pseudomonas vaccine
WO2017005670A1 (en) * 2015-07-04 2017-01-12 Evaxion Biotech Aps Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3718591A1 (de) * 1987-06-03 1988-12-15 Behringwerke Ag Aeusseres membranprotein f von pseudomonas aeruginosa
DE3829616C2 (de) * 1988-09-01 1996-08-29 Behringwerke Ag Lipoprotein I (OMPI) von Pseudomonas aeruginosa
US5196320A (en) * 1989-09-20 1993-03-23 Abbott Biotech, Inc. Method of producing engineered binding proteins
WO1993024636A1 (en) * 1992-05-29 1993-12-09 The University Of British Columbia Use of protein oprf for bacterial cell surface expression of oligopeptides

Also Published As

Publication number Publication date
JP3762779B2 (ja) 2006-04-05
US6300102B1 (en) 2001-10-09
CA2165401A1 (en) 1996-06-17
JP2005097321A (ja) 2005-04-14
JP3712244B2 (ja) 2005-11-02
US5955090A (en) 1999-09-21
AU4041995A (en) 1996-06-27
KR960022559A (ko) 1996-07-18
DE69515613T2 (de) 2000-11-30
EP0717106B1 (de) 2000-03-15
DE69515613D1 (de) 2000-04-20
EP0717106A1 (de) 1996-06-19
CA2165401C (en) 2010-05-11
JPH08245699A (ja) 1996-09-24

Similar Documents

Publication Publication Date Title
ATE190657T1 (de) Immunogenes hybridprotein oprf-oprl erhältlich aus membranproteinen von pseudomonas aeruginosa
ATE430200T1 (de) Impstoff gegen den für atemwegs- und reproduktionserkrankungen beim schwein verantwortlichen virus
DE69535795D1 (de) Polynukleinsäuren und proteine aus einem "porcine reproductive and respiratory syndrome virus" und ihre verwendung
ATE223229T1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
NO20003526L (no) Proteiner kodet av polynukleinsyrer fra svinereproduktive- og respiratoriske syndromvirus (PRRSV)
ATE207080T1 (de) Multivalente antigen-bindende proteine
EP0746398A4 (de) Antikörperreinigung
DK0821695T3 (da) Oprensning af antistof ved hydrofob interaktionschromatografi ved lav pH-værdi
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
ATE442866T1 (de) Fusionsproteine aus mycobakterium tuberculosis
DE59209129D1 (de) Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression
DE59209921D1 (de) Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2
DK47286D0 (da) Hundeparvovirus-vacciner
ATE342920T1 (de) Methylierte smd homologe peptide, die mit antikörpern aus sera von lebewesen mit systemischer lupus erythematodes reagieren
DE69915320D1 (de) Immunoglobulin-bindende proteine
ATE230418T1 (de) Monoklonaler antikörper gegen das humane mx- protein mxa
CA2137280A1 (fr) Clonage du gene codant pour la proteine gp28.5 de toxoplasma gondii; fragments peptidiques de cette proteine et leurs applications
AU7004894A (en) Synthetic peptides and vaccines against parvovirus
DE69941051D1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier
WO1991010735A3 (fr) Recepteur humain de la tsh. sequence codant pour ce recepteur
WO1996022372A3 (en) Antibodies for the control of cyst nematodes and transgenic plants expressing them
GB2299994A (en) Equine arteritis virus peptides antibodies and their use in a diagnostic test
ES2114527T3 (es) Anticuerpos que reconocen especificamente la proteina de enlace de la somatotropina.
PT998493E (pt) Epitopos de toxina semelhante a shigella e a sua utilizacao como vacinas e em diagnosticos
MX9604182A (es) Vacunas contra parasitos helminticos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification